Vaxxa redovisade ett starkt omsättningslyft i Q2 2026, där nettoomsättningen ökade med 57 % till 29,...
Redeye comments on CLS’s rights issue announcement and updates its valuation of the company accordin...
Redeye retains its positive view of Hansa Biopharma following a transformative second quarter.
Genovis Q2 2026 was characterised by strategic expansion following the KPL acquisition and encouragi...
Stille's Q2 2026 report beat our estimates on sales by ~7%, but showed softer margins than we had pe...
Aiforia issued a profit warning with H1'26 revenues coming in at a mere € 0.
The prostate theranostics market is expanding fast.
Tonies looks set to report a strong Q2 marked by further accelerating growth, carried by particularl...
Dynavox delivered an in-line topline but a clear profitability beat in Q2, with the EBIT margin alre...
Eastnine erbjuder en unik exponering mot Östeuropas strukturella tillväxt genom moderna prime-kontor...
Atria's Q2 adjusted EBIT of EUR 20.7m was 15% above LSEG Data & Analytics consensus and sales were 1...
Redeye updates its estimates and valuation after Lagercrantz’s Q1 2026/2027 report.
* Q2 volumes pre-announced, we forecast sales -13%, EBIT -28% * Comps ease from Q3, both FX and volu...
* Q2 broadly in line across most line items * '26e-'28e adj.
Redeye updates its estimates and valuation following MedCap’s Q2 2026 report, a broad-based beat ver...
* Order intake +5% y-o-y – an early sign of stabilisation? * We keep '26e adj.
* Launches bike-sharing service with ~700 bikes in Helsinki * Unlikely to trigger material consensus...
* -1%/0% adj. EBITDA vs ABGSCe/Infront cons in Q2 * Cons estimates likely unchanged * Trading at 10.
Yesterday, NanoRepro AG published its consolidated preliminary H1'26 revenue while also highlighting...
Yesterday, MHP released Q2 '26 hotel performance figures, posting the highest quarterly revenue in t...